";s:4:"text";s:5023:" barbituric, anesthesic agents) the risk of hepatotoxicity increases due to the production of isoniazid's reactive metabolites. This is similar to the findings of earlier studies [The only other prospective clinical trial of anti-TB drug reintroduction after DIH was conducted in Turkey by Tahaoglu et al [The present study also revealed pretreatment serum albumin level to be an important predictor of a second recurrence of DIH. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Of the clinical and baseline laboratory parameters analyzed, pretreatment serum albumin level was the only statistically significant predictor of future recurrence of DIH. Light chain proteinuria and humoral immunocompetence in tuberculosis patients treated with rifampin. Four patients died before they could be randomized into any of the 3 arms (3 patients died due to acute liver failure, and 1 patient died due to progressive pulmonary TB leading to acute respiratory failure). In the pres ent study, the severity of the first episode of DIH did not affect the risk of recurrence of DIH.Hepatotoxicity is the most common adverse effect of anti-TB treatment that leads to interruption of therapy [This study is, to our knowledge, the first to compare 3 different predefined anti-TB drug reintroduction regimens in a fairly large sample population. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme inductionIsoniazid hepatoxicity: The relationship between covalent binding and metabolism in vivoIncreased risk of antituberculosis drug‐induced hepatotoxicity in individuals with glutathione S‐transferase M1 "null" mutationPolymorphism of the N‐acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug‐induced hepatitisPyrazinamide fulminant hepatitis: An old hepatotoxin strikes again[Toxicity of pyrazinamide in antituberculous treatments.
When the liver chemistries normalized or improved by at least 50%, INH, RBT, and PZA were reintroduced, one at a time. DIH, drug-induced hepatotoxicity; HIV, human immunodeficiency virus; TB, tuberculosis.Summary of the study. The interferons: mechanism of action and clinical application. This patient, as stated previously, was also coinfected with HCV. By continuing to browse this site, you agree to its use of cookies as described in our I have read and accept the Wiley Online Library Terms and Conditions of UseDeleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazidIsoniazid–rifampin fulminant hepatitis. Hepatotoxicity of antituberculous therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis?